(Q37921593)

25 August 2017

1 reference

title

Predictive biomarkers: a paradigm shift towards personalized cancer medicine (English)

1 reference

25 August 2017

0 references

1 reference

Nicholas B La Thangue

series ordinal

1

1 reference

25 August 2017

David J Kerr

series ordinal

2

1 reference

25 August 2017

language of work or name

English

0 references

publication date

23 August 2011

1 reference

Nature Reviews Clinical Oncology

25 August 2017

published in

1 reference

25 August 2017

volume

8

1 reference

25 August 2017

issue

10

1 reference

25 August 2017

page(s)

587-596

1 reference

Costs of cancer care in the USA: a descriptive review.

25 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.121

Synthetic lethal RNAi screening identifies sensitizing targets for gemcitabine therapy in pancreatic cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.121

Personalized medicine in oncology: the future is now.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.121

Predictive biomarkers in the development of oncology drugs: a therapeutic industry perspective.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.121

A personalized approach to cancer treatment: how biomarkers can help

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.121

Rationale for biomarkers and surrogate end points in mechanism-driven oncology drug development

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.121

Analytical validation of the Oncotype DX genomic diagnostic test for recurrence prognosis and therapeutic response prediction in node-negative, estrogen receptor-positive breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.121

Identification of serum biomarkers for colon cancer by proteomic analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.121

Pharmacodynamic biomarkers for molecular cancer therapeutics

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.121

Pharmacodynamics in cancer therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.121

Market watch: emerging companion diagnostics for cancer drugs

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.121

31 March 2020

Targeted cancer therapy

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.121

Evolving treatment of advanced colon cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.121

Management of bevacizumab-associated bowel perforation: a case series and review of the literature

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.121

Evolution of biomarker qualification at the health authorities

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.121

NICE and the challenge of cancer drugs

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.121

A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.121

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.121

Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.121

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.121

Trastuzumab--mechanism of action and use in clinical practice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.121

Molecular targets for breast cancer therapy and prevention

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.121

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.121

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.121

Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.121

Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.121

Trastuzumab resistance: all roads lead to SRC

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.121

The HER2 testing conundrum

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.121

Clinical practice patterns and cost effectiveness of human epidermal growth receptor 2 testing strategies in breast cancer patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.121

Systematic review of HER2 breast cancer testing

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.121

Optimizing treatment of chronic myeloid leukemia: a rational approach

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.121

Specific targeted therapy of chronic myelogenous leukemia with imatinib

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.121

Heterogeneity in chronic myeloid leukaemia dynamics during imatinib treatment: role of immune responses.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.121

Drug developers unveil strategies aimed at imatinib-resistant CML.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.121

Hematology: Nilotinib and dasatinib--new 'magic bullets' for CML?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.121

Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.121

Nilotinib: a second-generation tyrosine kinase inhibitor for chronic myeloid leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.121

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.121

31 March 2020

Chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.121

Gene and drug matrix for personalized cancer therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.121

Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.121

The role of companion diagnostics in the development and use of mutation-targeted cancer therapies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.121

Imatinib: a review of its use in the management of gastrointestinal stromal tumours

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.121

Imatinib treatment of metastatic GIST: don't stop (believing).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.121

Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.121

EGFR antagonists in cancer treatment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.121

Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.121

Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.121

Colorectal cancer in review: the role of the EGFR pathway

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.121

Oncogenic mutations as predictive factors in colorectal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.121

Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.121

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.121

Predicting response to EGFR inhibitors in metastatic colorectal cancer: current practice and future directions

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.121

FDA holds court on post hoc data linking KRAS status to drug response

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.121

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.121

Erlotinib in non-small cell lung cancer treatment: current status and future development

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.121

Targeted therapies: Tyrosine-kinase inhibitors--new standard for NSCLC therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.121

Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.121

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.121

Targeted therapies: Importance of patient selection for EGFR TKIs in lung cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.121

KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.121

The biology and treatment of EML4-ALK non-small cell lung cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.121

Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.121

Small molecule kinase inhibitors in glioblastoma: a systematic review of clinical studies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.121

PTEN-mediated resistance to epidermal growth factor receptor kinase inhibitors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.121

Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.121

Retinoic acid receptors and cancers.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.121

Acquisition of oncogenic potential by RAR chimeras in acute promyelocytic leukemia through formation of homodimers.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.121

Retinoids in cancer therapy and chemoprevention: promise meets resistance

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.121

Frequent mutations in the ligand-binding domain of PML-RARalpha after multiple relapses of acute promyelocytic leukemia: analysis for functional relationship to response to all-trans retinoic acid and histone deacetylase inhibitors in vitro and in v

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.121

Retinoids, retinoic acid receptors, and cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.121

The histone deacetylase (HDAC) inhibitor valproic acid as monotherapy or in combination with all-trans retinoic acid in patients with acute myeloid leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.121

Histone deacetylase inhibitors regulate retinoic acid receptor beta expression in neuroblastoma cells by both transcriptional and posttranscriptional mechanisms

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.121

Breast and ovarian cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.121

The concept of synthetic lethality in the context of anticancer therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.121

A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.121

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.121

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.121

Current development of clinical inhibitors of poly(ADP-ribose) polymerase in oncology

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.121

Triple-Negative Breast Cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.121

Iniparib plus chemotherapy in metastatic triple-negative breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.121

Targeted therapies: PARP inhibitor olaparib is safe and effective in patients with BRCA1 and BRCA2 mutations

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.121

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.121

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.121

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.121

Combinatorial treatments that overcome PDGFRβ-driven resistance of melanoma cells to V600EB-RAF inhibition

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.121

Loss-of-function genetic screens as a tool to improve the diagnosis and treatment of cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.121

Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.121

Identification of CDK10 as an important determinant of resistance to endocrine therapy for breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.121

Genome-wide loss-of-function screen reveals an important role for the proteasome in HDAC inhibitor-induced apoptosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.121

HR23B is a biomarker for tumor sensitivity to HDAC inhibitor-based therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.121

HDAC inhibitor-based therapies and haematological malignancy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.121

Proteasome and HDAC: who's zooming who?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.121

Synthetic lethal screen identification of chemosensitizer loci in cancer cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.121

Cancer clinical trials--a chronic but curable crisis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.121

BCR-ABL mutation testing to predict response to tyrosine kinase inhibitors in patients with chronic myeloid leukemia

31 March 2020

1 reference

12 December 2020

The PML/RAR alpha fusion gene in the diagnosis and monitoring of acute promyelocytic leukemia.

1 reference

12 December 2020

Use of erlotinib or gefitinib as initial therapy in advanced NSCLC.

1 reference

12 December 2020

HER2 testing in patients with breast cancer: poor correlation between weak positivity by immunohistochemistry and gene amplification by fluorescence in situ hybridization

1 reference

12 December 2020

10.1038/NRCLINONC.2011.121

Identifiers

DOI

1 reference

25 August 2017

1 reference